Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.45 |
| ▸ | WNT1 | P04628 | 10/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25644934 | 1.00 | GSK3B (0.45) | GSK3BDYRK1AWNT1DYRK3CLK1 | |
| SCHEMBL25421944 | 0.85 | DYRK1A (0.58) | GSK3BDYRK1AWNT1DYRK3CLK1 | |
| SCHEMBL30461690 | 0.85 | DYRK1A (0.58) | GSK3BDYRK1AWNT1DYRK3CLK1 | |
| SCHEMBL30461623 | 0.84 | DYRK1A (0.42) | GSK3BDYRK1ADYRK3CLK1CLK2 | |
| SCHEMBL25421734 | 0.84 | DYRK1A (0.42) | GSK3BDYRK1ADYRK3CLK1CLK2 | |
| SCHEMBL31472517 | 0.82 | DYRK1B (0.48) | GSK3BDYRK1AWNT1DYRK3CLK1 | |
| SCHEMBL25644903 | 0.82 | DYRK1B (0.48) | GSK3BDYRK1AWNT1DYRK3CLK1 | |
| SCHEMBL25643414 | 0.77 | CDK2 (0.35) | GSK3BDYRK1AWNT1DYRK1BROCK2 | |
| SCHEMBL2228251 | 0.76 | DYRK1A (0.46) | GSK3BDYRK1ADYRK1BNFATC1CCND1 | |
| SCHEMBL30461606 | 0.74 | BCDIN3D (0.43) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | GSK3B 80/4885DYRK1A 2/4885WNT1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.